| Species |
Human |
| Protein Construction |
B7-H7/HHLA2 (Ile23-Asn344)
Accession # Q9UM44-1 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human CD28H, His Tag at 5μg/ml (100μl/well) on the plate can bind B7-H7/HHLA2 hFc Chimera, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
63.7 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 78-100 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
B7-H7, also known as HHLA2 (HERV-H LTR-associating 2), is a member of the B7 family of immune regulatory proteins.Through interaction with TMIGD2, costimulates T-cells in the context of TCR-mediated activation. Enhances T-cell proliferation and cytokine production via an AKT-dependent signaling cascade. |
| Synonyms |
B7H7; B7-H7; HHLA2; B7 Homolog 7 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
